Advertisement

Topics

Beta Blocker Interruption After Uncomplicated Myocardial Infarction

2018-04-20 09:47:10 | BioPortfolio

Published on BioPortfolio: 2018-04-20T09:47:10-0400

Clinical Trials [2253 Associated Clinical Trials listed on BioPortfolio]

TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the...

IRIS : Use of Implantable Defibrillator in High-Risk Patients Early After Acute Myocardial Infarction

Of the patients who survive hospitalization after an acute myocardial infarction, ca. 10% die of sudden cardiac death in the following 2 years. The prognosis appears not improved by medica...

Randomized Evaluation of Decreased Usage of betablocCkErs After Myocardial Infarction in the SWEDEHEART Registry

Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study ...

Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China

Beta Blocker therapy is a mainstay of treatment following acute coronary syndromes (ACS), particularly acute myocardial infarction (MI). Studies have repeatedly demonstrated the benefit of...

Occluded Artery Trial (OAT)

The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composi...

PubMed Articles [18979 Associated PubMed Articles listed on BioPortfolio]

Effect of β-Blockers Beyond 3 Years After Acute Myocardial Infarction.

The optimal duration of β-blocker therapy in patients with acute myocardial infarction (AMI) is unknown. We aimed to evaluate the late effect of β-blockers in patients with AMI.

In Current Clinical Practice, after Percutaneous Coronary Intervention for Acute Myocardial Infarction, Are β-Blockers Prescribed for Heart Failure or as Secondary Prevention? A Pilot Study.

Patients surviving an acute myocardial infarction (AMI) are different today than when oral β-blockers first were shown to have an incremental effect on mortality. They are now, as opposed to then, of...

Causes and prevention of postoperative myocardial injury.

Over the past few years non-cardiac surgery has been recognised as a serious circulatory stress test which may trigger cardiovascular events such as myocardial infarction, in particular in patients at...

Effect of Oral β-blocker Treatment on Mortality in Contemporary Post-myocardial Infarction Patients.

Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are based on studies undertaken before the implementation of reperfusion and secondary prevention therapies. We a...

Ophthalmic Technology Assessment: The Use of Beta-Blockers for the Treatment of Periocular Hemangiomas in Infants.

To review the published literature assessing the efficacy of beta-blockers for the treatment of periocular hemangioma in infants.

Medical and Biotech [MESH] Definitions

A myocardial infarction that does not produce elevations in the ST segments of the ELECTROCARDIOGRAM. ST segment elevation of the ECG is often used in determining the treatment protocol (see also ST Elevation Myocardial Infarction).

A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).

MYOCARDIAL INFARCTION in which the anterior wall of the heart is involved. Anterior wall myocardial infarction is often caused by occlusion of the left anterior descending coronary artery. It can be categorized as anteroseptal or anterolateral wall myocardial infarction.

A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent.

MYOCARDIAL INFARCTION in which the inferior wall of the heart is involved. It is often caused by occlusion of the right coronary artery.

More From BioPortfolio on "Beta Blocker Interruption After Uncomplicated Myocardial Infarction"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial